GlassScriptPhysician profile
William L Rowland
NPI 1639270200
$6,351.21
in general payments reported to CMS, 2019-2025
52 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $862 · 2021: $865 · 2022: $857 · 2023: $1,057 · 2024: $834 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $807.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $740.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $670.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $536.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.03 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $346.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $346.26 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.03 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $238.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $224.22 | 2019-2024 | Vraylar, Synthroid, Ubrelvy |
| Amarin Pharma, INC. | $215.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $210.32 | 2019-2025 | |
| Eisai INC. | $118.61 | 2020-2025 | |
| Allergan, INC. | $99.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $95.93 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rowland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.